Health
Phase 3 trial: New biologic therapy improves outcomes in adults, adolescents with severe asthma – News-Medical.Net
Results from the NAVIGATOR study of tezepelumab showed that the new biologic therapy significantly reduced exacerbations requiring hospital stays and emergency…
Results from the NAVIGATOR study of tezepelumab showed that the new biologic therapy significantly reduced exacerbations requiring hospital stays and emergency department (ED) visits for adults and adolescents with severe, uncontrolled asthma, according to research presented at the ATS 2021 International Conference. NAVIGATOR (NCT03347279) is a recently completed randomized, placebo-controlled double-blind multicenter phase 3 clinical trial.
Tezepelumab offers new therapeutic opportunities for patients…
-
Noosa News16 hours agoChild, 15, arrested over death of another child, 8, after shocking e-bike crash in Queensland
-
General14 hours agoCrowe toasts talkback titan for platforming ‘voiceless’
-
Noosa News15 hours agoLyka Doggie Date Night at Moonlight Cinema
-
Business16 hours agoSolid superannuation gains continue to roll in